BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Associates of Cape Cod, Inc. Release: Use of the Fungitell® Assay in the Diagnosis of Invasive Fungal Infections


11/14/2012 9:34:39 AM

EAST FALMOUTH, Mass., Nov. 14, 2012 /PRNewswire/ -- The Fungitell® assay, manufactured by Associates of Cape Cod, Inc. (ACC), is a FDA-cleared, highly sensitive, rapid diagnostic test that detects (1,3)-b-D-glucan in blood serum.  This assay is intended for use as a diagnostic aid in clinical situations where rapid results concerning Invasive Fungal Infection (IFI) are required; Fungitell® should be used in conjunction with other diagnostic procedures.

(Logo:  http://photos.prnewswire.com/prnh/20121114/NE12626LOGO )

(1,3)-b-D-glucan is produced by common primary human fungal pathogens such as Candida spp. and Aspergillus spp., as well as many opportunistic fungal pathogens. During infection, (1,3)-b-D-glucan produced by certain fungal pathogens may be released into the bloodstream and then detected by the Fungitell® assay using patient blood serum. 

"ACC is ready to offer support to clinicians who are concerned about the risk of fungal infections. We have an FDA-cleared product, extensive research, and significant experience in clinical testing associated with the diagnosis of IFI," stated Dr. AJ Meuse, ACC President and Chief Executive Officer.  "It is, however, important to note that the fungal organism most commonly associated with fungal meningitis in the current outbreak, Exserohilum rostratum, is currently uncharacterized relative to its contribution of (1,3)-b-D-glucan to the bloodstream."

Associates of Cape Cod, Inc. (ACC) is one of the world's largest manufacturers of products developed to detect and quantify Gram-negative bacterial endotoxins and (1,3)-b-D-glucans. Our products are used worldwide by leading pharmaceutical and medical device companies to ensure the safety of their parenteral drugs, biological products and medical devices. ACC's goal is to provide the best products and services, as well as the best technical support and customer service, to enhance the productivity and efficiency of all customers. ACC is ISO 13485:2003 certified, its laboratories are FDA Inspected and DEA Licensed and the Beacon Diagnostics® laboratory is CLIA certified.

ACC's corporate headquarters are located in East Falmouth, Massachusetts with offices in the UK and Germany. Founded in 1974, ACC was the first to be licensed by the FDA to manufacture LAL for use as a quality control test for endotoxin detection in the pharmaceutical and medical device markets. Over the years, ACC has grown to be an internationally recognized leader in endotoxin detection, with a distribution network servicing over 80 countries.

Contact: James Spitzer
508-540-3444
fungitell@acciusa.com
www.acciusa.com

SOURCE Associates of Cape Cod, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES